Cognito Therapeutics develops a non-invasive treatment for Alzheimer's disease that utilizes visual and auditory stimulation to evoke gamma wave activity in the brain, addressing abnormal neuronal activity associated with cognitive decline. Their Phase 2 clinical trial demonstrated a 56.4% reduction in dependence scores among treated patients, indicating significant preservation of cognitive function and daily living abilities.
Funding
$159.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Alzheimer's disease is characterized by abnormal neuronal activity in the brain, leading to impaired cognitive function, memory loss, and a decline in daily living abilities. Current treatments do not directly address this abnormal neuronal activity.
Solution
Cognito Therapeutics is developing Spectris, a non-invasive therapy designed to treat Alzheimer's disease by evoking gamma wave activity in the brain through visual and auditory stimulation. The therapy aims to address the abnormal neuronal activity associated with cognitive decline. Patients receive the treatment from home for one hour each day. Clinical studies have demonstrated a significant slowing of disease progression among treated patients, with preservation of cognition, daily function, and whole brain volume.
Target Audience
The primary target audience includes individuals diagnosed with Alzheimer's disease and their caregivers, as well as healthcare providers specializing in neurodegenerative diseases.
Features
- Non-invasive treatment delivered via a headset providing visual and auditory stimulation.
- Designed to evoke gamma wave activity in the brain.
- Intended for daily use in the patient's home.
- Demonstrated a 56.4% reduction in dependence scores in Phase 2 clinical trials.
- Aims to preserve cognitive function and daily living abilities.
- Targets abnormal neuronal activity associated with Alzheimer's disease.